Intest Res.  2015 Jul;13(3):219-226. 10.5217/ir.2015.13.3.219.

Tacrolimus for the Treatment of Ulcerative Colitis

• Matsuoka K
• Saito E
• Fujii T
• Takenaka K
• Kimura M
• Nagahori M
• Ohtsuka K
• Watanabe M

• KMID: 2174466
• DOI: http://doi.org/10.5217/ir.2015.13.3.219

Abstract

Tacrolimus is a calcineurin inhibitor used for the treatment of corticosteroid-refractory ulcerative colitis (UC). Two randomized controlled trials and a number of retrospective studies have assessed the therapeutic effect of tacrolimus in UC patients. These studies showed that tacrolimus has excellent short-term efficacy in corticosteroid-refractory patients, with the rates of clinical response ranging from 61% to 96%. However, the long-term prognosis of patients treated with tacrolimus is disappointing, and almost 50% of patients eventually underwent colectomy in long-term follow-up. Tacrolimus can achieve mucosal healing in 40-50% of patients, and this is associated with a favorable long-term prognosis. Anti-tumor necrosis factor (TNF)-alpha antibodies are another therapeutic option in corticosteroid-refractory patients. A prospective head-to-head comparative study of tacrolimus and infliximab is currently being performed to determine which treatment is more effective in corticosteroid-refractory patients. Several retrospective studies have demonstrated that switching between tacrolimus and anti-TNF-alpha antibody therapy was effective in patients who were refractory to one of the treatments. Most adverse events of tacrolimus are mild; however, opportunistic infections, especially pneumocystis pneumonia, are the most important adverse events, and these should be carefully considered during treatment. Several issues on tacrolimus treatment in UC patients remain unsolved (e.g., use of tacrolimus as remission maintenance therapy). Further controlled studies are needed to optimize the use of tacrolimus for the treatment of UC.

Keyword

Tacrolimus; Colitis, ulcerative; Cyclosporine; Calcineurin inhibitors

MeSH Terms

Antibodies
Calcineurin
Colectomy
Colitis, Ulcerative*
Cyclosporine
Follow-Up Studies
Humans
Infliximab
Necrosis
Opportunistic Infections
Pneumonia, Pneumocystis
Prognosis
Tacrolimus*
Antibodies
Calcineurin
Cyclosporine
Tacrolimus

Reference

1. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994; 330:1841–1845. PMID: 8196726.

2. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987; 40:1256–1265. PMID: 2445722.

3. Hirano T, Akashi T, Kido T, Oka K, Shiratori T, Miyaoka M. Immunosuppressant pharmacodynamics on peripheral-blood mononuclear cells from patients with ulcerative colitis. Int Immunopharmacol. 2002; 2:1055–1063. PMID: 12349943.

4. Fellermann K, Ludwig D, Stahl M, David-Walek T, Stange EF. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol. 1998; 93:1860–1866. PMID: 9772045.

5. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006; 55:1255–1262. PMID: 16484504.

6. Ogata H, Kato J, Hirai F, et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2012; 18:803–808. PMID: 21887732.

7. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis. 2002; 8:317–324. PMID: 12479646.

8. Högenauer C, Wenzl HH, Hinterleitner TA, Petritsch W. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther. 2003; 18:415–423. PMID: 12940927.

9. Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 17:1273–1281. PMID: 12755840.

10. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease-a long-term follow-up. Am J Gastroenterol. 2006; 101:1048–1056. PMID: 16573777.

11. Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13:129–134. PMID: 17206694.

12. Yamamoto S, Nakase H, Mikami S, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther. 2008; 28:589–597. PMID: 18549460.

13. Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis. 2008; 14:7–12. PMID: 17879277.

14. Herrlinger KR, Koc H, Winter S, et al. ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clin Pharmacol Ther. 2011; 89:422–428. PMID: 21289623.

15. Schmidt KJ, Herrlinger KR, Emmrich J, et al. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. Aliment Pharmacol Ther. 2013; 37:129–136. PMID: 23121200.

16. Thin LW, Murray K, Lawrance IC. Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era. Inflamm Bowel Dis. 2013; 19:1490–1498. PMID: 23615528.

17. Mizoshita T, Tanida S, Tsukamoto H, et al. Colon mucosa exhibits loss of ectopic MUC5AC expression in patients with ulcerative colitis treated with oral tacrolimus. ISRN Gastroenterol. 2013; 2013:304894. PMID: 23691335.

18. Landy J, Wahed M, Peake ST, et al. Oral tacrolimus as maintenance therapy for refractory ulcerative colitis-an analysis of outcomes in two London tertiary centres. J Crohns Colitis. 2013; 7:e516–e521. PMID: 23623737.

19. Hirai F, Takatsu N, Yano Y, et al. Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus. J Gastroenterol Hepatol. 2014; 29:60–66. PMID: 24033383.

20. Kawakami K, Inoue T, Murano M, et al. Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis. World J Gastroenterol. 2015; 21:1880–1886. PMID: 25684955.

21. Ikeya K, Sugimoto K, Kawasaki S, et al. Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis. Dig Liver Dis. 2015; 47:365–371. PMID: 25682993.

22. Miyoshi J, Matsuoka K, Inoue N, et al. Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. J Crohns Colitis. 2013; 7:e609–e614. PMID: 23680174.

23. Watson S, Pensabene L, Mitchell P, Bousvaros A. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis. 2011; 17:22–29. PMID: 20722055.

24. Bousvaros A, Kirschner BS, Werlin SL, et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr. 2000; 137:794–799. PMID: 11113835.

25. Ziring DA, Wu SS, Mow WS, Martín MG, Mehra M, Ament ME. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr. 2007; 45:306–311. PMID: 17873742.

26. Boschetti G, Nancey S, Moussata D, et al. Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatment. Dig Liver Dis. 2014; 46:875–880. PMID: 25023007.

27. Yamamoto S, Nakase H, Matsuura M, Masuda S, Inui K, Chiba T. Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis. J Clin Gastroenterol. 2011; 45:526–530. PMID: 21336140.

28. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353:2462–2476. PMID: 16339095.

29. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011; 60:780–787. PMID: 21209123.

30. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012; 380:1909–1915. PMID: 23063316.

31. Naves JE, Llaó J, Ruiz-Cerulla A, et al. Long-term comparative efficacy of cyclosporine- or infliximab-based strategies for the management of steroid-refractory ulcerative colitis attacks. Inflamm Bowel Dis. 2014; 20:1375–1381. PMID: 25046008.

32. Croft A, Walsh A, Doecke J, Cooley R, Howlett M, Radford-Smith G. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol Ther. 2013; 38:294–302. PMID: 23786158.

33. Dean KE, Hikaka J, Huakau JT, Walmsley RS. Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis. J Gastroenterol Hepatol. 2012; 27:487–492. PMID: 22098019.

34. Mocciaro F, Renna S, Orlando A, et al. Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study. J Crohns Colitis. 2012; 6:681–686. PMID: 22398101.

35. Minami N, Yoshino T, Matsuura M, et al. Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study. BMJ Open Gastro. 2010; DOI: 10.1136/bmjgast-2014-000021. Published online 20 February 2015.

36. Herrlinger KR, Barthel DN, Schmidt KJ, et al. Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. Aliment Pharmacol Ther. 2010; 31:1036–1041. PMID: 20175769.

37. Tsukamoto H, Tanida S, Mizoshita T, et al. Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus. Eur J Gastroenterol Hepatol. 2013; 25:714–718. PMID: 23411870.

38. Yamamoto S, Nakase H, Matsuura M, et al. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. J Gastroenterol Hepatol. 2010; 25:886–891. PMID: 20546441.

39. Leblanc S, Allez M, Seksik P, et al. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am J Gastroenterol. 2011; 106:771–777. PMID: 21386832.

40. Saito E, Nagahori M, Fujii T, Ohtsuka K, Watanabe M. Efficacy of salvage therapy and its effect on operative outcomes in patients with ulcerative colitis. Digestion. 2014; 89:55–60. PMID: 24458114.

41. Lainesse A, Hussain S, Monif T, et al. Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. Arzneimittelforschung. 2008; 58:242–247. PMID: 18589558.

42. van Dieren JM, van Bodegraven AA, Kuipers EJ, et al. Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis. 2009; 15:193–198. PMID: 18825773.

43. Lawrance IC, Copeland TS. Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther. 2008; 28:1214–1220. PMID: 18761706.

44. Uchino M, Ikeuchi H, Matsuoka H, et al. Topical tacrolimus therapy for antibiotic-refractory pouchitis. Dis Colon Rectum. 2013; 56:1166–1173. PMID: 24022534.

45. Gonzalez-Lama Y, Gisbert JP, Mate J. The role of tacrolimus in inflammatory bowel disease: a systematic review. Dig Dis Sci. 2006; 51:1833–1840. PMID: 16964541.

46. Escher M, Stange EF, Herrlinger KR. Two cases of fatal Pneumocystis jirovecii pneumonia as a complication of tacrolimus therapy in ulcerative colitis-a need for prophylaxis. J Crohns Colitis. 2010; 4:606–609. PMID: 21122569.

47. Hida N, Nakamura S, Hahm KB, et al. A questionnaire-based survey on the diagnosis and management of inflammatory bowel disease in East Asian countries in 2012. Digestion. 2014; 89:88–103. PMID: 24458117.